Michigan Medicine enters drug discovery collaboration with AstraZeneca in Chronic Kidney Disease

ANN ARBOR—Patients with Chronic Kidney Disease (CKD) may benefit from a new collaboration between the University of Michigan (U-M) and AstraZeneca who have partnered to develop a new therapeutic strategy for treatment. The partners will jointly conduct chemistry and drug discovery research with the aim of developing candidate drugs. 

Read the full story from Michigan Medicine.

share this